Sage Journals: Discover world-class research

Abstract

To establish measures for improving the productivity of pharmaceutical R&D, we tested the academic efficiency of PharmaPipelines, a comprehensive database covering 77 companies worldwide for all observable pharmaceutical development projects. We found that the present database is sustainable for academic validation in terms of coverage and prediction accuracy through statistical validation. On reviewing project value allocations, the value-based assessment results provided essential implications as compared to conventional volume-based assessment, particularly for consolidated project value allocations for pharmaceutical and biotech companies with large market capitalization throughout the developmental phases. Furthermore, we confirmed that R&D productivity and scale are inversely proportional and clustering of the distribution pattern by company category. These observation results were obtained on the basis of economic value and are therefore expected to be valuable for strategic R&D planning at company level as well as providing a quantitative foundation for planning and validation of industrial research policies.

Keywords

Pharmaceutical R&D Net present value Valuation Project management R&D productivity

Get full access to this article

View all access options for this article.

References

Bolten

DeGregorio

. Trends in development cycles. Nat Rev Drug Discovery. 2002; 1: 335–336.

Booth

Zemmel

. Prospects for productivity. Nat Rev Drug Discovery. 2004; 3: 451–456.

Reichert

. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discovery. 2003; 2: 695–702.

DiMasi

Grabowski

Vernon

. R&D costs and returns by therapeutic category. Drug Inf J. 2004; 138: 211–223.

Hartmann

Hassan

. Application of real options analysis for pharmaceutical R&D project valuation—empirical results from a survey. Res Pol. 2006; 35: 343–354.

Girotra

Terwiesch

Ulrich

. Valuing R&D projects in a portfolio: Evidence from the pharmaceutical industry. Manage Sci. 2007; 53: 1452–1466.

Smith

Nau

. Valuing risky projects: Option pricing theory and decision analysis. Manage Sci. 1995; 41: 795–816.

Loch

Bode-Greuel

. Evaluating growth options as sources of value for pharmaceutical research projects. R&D Manage. 2001; 31: 231–244.

Black

Scholes

. The pricing of options and corporate liabilities. J Pol Econ. 1973; 81: 637–659.

10.

Merton

. Theory of rational option pricing. Bell J Econ Manage Sci. 1973; 4: 141–183.

11.

Copeland

Koller

Murrin

. Valuation: Measuring and Managing the Value of Companies. New York: Wiley; 2000.

12.

Vernon

Gusen

. Technical change and firm size: The pharmaceutical industry. Rev Econ Stat. 1974; 56: 294–302.

13.

Graves

Langowitz

. Innovative productivity and returns to scale in the pharmaceutical industry. Strategic Manage J. 1993; 14: 593–605.

14.

Ministry of Health, Labour and Welfare of Japan.

New Vision for the Pharmaceutical Industry: Aiming at the Industry With International Competitive Power Taking the Mission of Innovation. 2008:33–42.

Assessment of Pharmaceutical Research and Development Productivity with a Novel Net Present Value-based Project Database

Abstract

Keywords

Get full access to this article

References